These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25055029)

  • 21. Highly Synergistic Effects of Melittin with Conventional Antibiotics Against Multidrug-Resistant Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa.
    Akbari R; Hakemi-Vala M; Pashaie F; Bevalian P; Hashemi A; Pooshang Bagheri K
    Microb Drug Resist; 2019 Mar; 25(2):193-202. PubMed ID: 30281385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of tachyplesin III against Pseudomonas aeruginosa.
    Cirioni O; Giacometti A; Kamysz W; Silvestri C; Riva A; Della Vittoria A; Abbruzzetti A; Lukasiak J; Scalise G
    Peptides; 2007 Apr; 28(4):747-51. PubMed ID: 17331619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antibiotic combinations for colistin-resistant Klebsiella pneumoniae.
    Kádár B; Kocsis B; Tóth Á; Damjanova I; Szász M; Kristóf K; Nagy K; Szabó D
    Acta Microbiol Immunol Hung; 2013 Jun; 60(2):201-9. PubMed ID: 23827751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F; Quentin C
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
    Holger DJ; Lev KL; Kebriaei R; Morrisette T; Shah R; Alexander J; Lehman SM; Rybak MJ
    J Appl Microbiol; 2022 Sep; 133(3):1636-1649. PubMed ID: 35652690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Oie S; Fukui Y; Yamamoto M; Masuda Y; Kamiya A
    BMC Infect Dis; 2009 Aug; 9():123. PubMed ID: 19664245
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Pahlavanzadeh F; Kalantar-Neyestanaki D; Motamedifar M; Mansouri S
    Yale J Biol Med; 2020 Mar; 93(1):29-34. PubMed ID: 32226332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates.
    Jahangiri A; Neshani A; Mirhosseini SA; Ghazvini K; Zare H; Sedighian H
    Microb Pathog; 2021 Jan; 150():104700. PubMed ID: 33346078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
    Zhanel GG; Mayer M; Laing N; Adam HJ
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro efficacy of colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration.
    Gill MM; Rao JU; Kaleem F; Hassan A; Khalid A; Anjum R
    Pak J Pharm Sci; 2013 Jan; 26(1):7-10. PubMed ID: 23261721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Guzel C; Savage PB; Gerceker AA
    Chemotherapy; 2011; 57(6):505-10. PubMed ID: 22286090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
    Deveci A; Coban AY; Acicbe O; Tanyel E; Yaman G; Durupinar B
    J Chemother; 2012 Oct; 24(5):247-52. PubMed ID: 23182043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
    Pankey GA; Ashcraft DS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2959-64. PubMed ID: 15980375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Sambatakou H; Galani I; Giamarellou H
    J Chemother; 2003 Jun; 15(3):235-8. PubMed ID: 12868548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
    Buyck JM; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea.
    Lee JY; Song JH; Ko KS
    Microb Drug Resist; 2011 Jun; 17(2):299-304. PubMed ID: 21381965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using host-mimicking conditions and a murine cutaneous abscess model to identify synergistic antibiotic combinations effective against
    Lyons N; Wu W; Jin Y; Lamont IL; Pletzer D
    Front Cell Infect Microbiol; 2024; 14():1352339. PubMed ID: 38808066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.